Oncotarget

Research Papers:

Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy

Bo Zhang, Wei Shi, Ting Jiang, Lanting Wang, Heng Mei, Heng Lu, Yu Hu _ and Zhiqing Pang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:62607-62618. https://doi.org/10.18632/oncotarget.11546

Metrics: PDF 2354 views  |   HTML 3369 views  |   ?  


Abstract

Bo Zhang1,*, Wei Shi1,*, Ting Jiang1, Lanting Wang2,3, Heng Mei1,4, Heng Lu2, Yu Hu1,4, Zhiqing Pang2

1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, PR China

2Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, China

3School of Medicine, Fudan University, Shanghai, China

4Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, China

*These authors have contributed equally to this work

Correspondence to:

Yu Hu, email: [email protected]

Zhiqing Pang, email: [email protected]

Keywords: tumor microenvironment, imatinib mesylate, nanoparticles, micelles, nanomedicine size

Received: April 02, 2016     Accepted: August 10, 2016     Published: August 23, 2016

ABSTRACT

Effective delivery of nanomedicines to tumor tissues depends on both the tumor microenvironment and nanomedicine properties. Accordingly, tumor microenvironment modification or advanced design of nanomedicine was emerging to improve nanomedicine delivery to tumors. However, few studies have emphasized the necessity to optimize the tumor microenvironment and nanomedicine properties simultaneously to improve tumor treatment. In the present study, imatinib mesylate (IMA) was used to normalize the tumor microenvironment including platelet-derived growth factor receptor-β expression inhibition, tumor vessel normalization, and tumor perfusion improvement as demonstrated by immunofluorescence staining. In addition, the effect of tumor microenvironment normalization on tumor delivery of nanomedicines with different sizes was carefully investigated. It was shown that IMA treatment significantly reduced the accumulation of nanoparticles (NPs) around 110 nm but enhanced the accumulation of micelles around 23 nm by in vivo fluorescence imaging experiment. Furthermore, IMA treatment limited the distribution of NPs inside tumors but increased that of micelles with a more homogeneous pattern. Finally, the anti-tumor efficacy study displayed that IMA pretreatment could significantly increase the therapeutic effects of paclitaxel-loaded micelles. All-together, a new strategy to improve nanomedicine delivery to tumor was provided by optimizing both nanomedicine size and the tumor microenvironment simultaneously, and it will have great potential in clinics for tumor treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11546